April 2020
COVID-19 and scarce hospital resources: B·R·A·H·M·S MR-proADM for risk stratification to support decisions on the required level of care
The biomarker mid-regional proadrenomedullin (MR-proADM) allows an easier and more accurate risk assessment in pneumonia patients compared to standard clinical scores (e.g. SOFA), independent of etiology, i.e. viral, bacterial or combined infection. Thus, MR-proADM testing is a useful tool to improve early detection of organ dysfunction and progression to sepsis and septic shock. In conjunction with clinical evaluation and other laboratory findings, MR-proADM can be used as an aid to support decision on patient disposition.
News Archive
2019
November 2019
MR-proADM in Suspected Infection
MR-proADM test for use with clinical deterioration scores in cases of suspected infection
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection. The main points from the evidence summarised in this briefing are from 5 observational studies of 3,217 people with suspected infections in hospital. They show that MR-proADM can improve accuracy of infection diagnosis and can predict the infection's severity.
Read the full publication here >
May 2019
Sepsis / Emergency Department (ED)
New Study Results Find That The Blood Biomarker MR-proADM May Prevent Early Hospital Discharge in Patients with Developing Sepsis
Multi-centre analysis shows that incorporation of MR-proADM (mid-regional proadrenomedullin) into an early management of patients with suspected infection protocol may aid rapid clinical decision making in the emergency department
2018
May 2018
MR-proADM in Urinary Tract Infections
Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection
Objectives: Febrile urinary tract infections (fUTI) can often be treated safely with oral antimicrobials in an outpatient setting. However, a minority of patients develop complications that may progress into septic shock.
Read the full publication here >
May 2018
MR-proADM in Sepsis
Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores
An early identification of sepsis patients likely to progress towards multiple organ failure is crucial in order to initiate targeted therapeutic strategies to decrease mortality.
Read the full publication here >
April 2018
MR-proADM in Sepsis and Cancer
Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin with Emphasis in Patients with Cancer
Sepsis and bloodstream infections remain a leading cause of death in immunocompromised patients with cancer. The management of these serious infections consist of empiric use of antimicrobial agents which are often overused.
Read the full publication here >
March 2018
MR-proADM in Cardiology
Adrenomedullin: Continuing to explore cardioprotection
Adrenomedullin (AM), a peptide isolated from an extract of human pheochromocytoma, comprises 52 amino acids with an intramolecular disulfide bond and amidation at the carboxy-terminus.
Read the full publication here >
March 2018
MR-proADM in community-acquired pneumonia (CAP)
Multidimensional Prognostic Index (MPI) and Proadrenomedullin plasma levels in predicting one-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP): a prospective study
Background: To evaluate the prognostic accuracy of proadrenomedullin (proADM) in comparison with and in addition to the Multidimensional Prognostic Index (MPI), a validated predictive tool for mortality derived from a comprehensive geriatric assessment (CGA) to predict one-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP).
Read the full publication here >
March 2018
MR-proADM in Sepsis
The use of MR-proADM in assessing disease severity and treatment response in patients with sepsis and septic shock
In collaboration with the SepNet Critical Care Trials Group, a new analysis of 1089 patients with sepsis and septic shock across 33 German Intensive Care Units was recently published in Critical Care. MR-proADM could add significant value to identifying patients at risk of further disease progression, the earlier escalation of therapy in patients at risk of treatment failure, and the subsequent de-escalation of treatment and early discharge of low risk patients.
Read the News Press Release here >
Read the full publication here >
February 2018
MR-proADM in the Laboratory
Plasma mid-regional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population
Robust reference intervals for MR-proADM concentrations in plasma were generated, with the recommended adoption of single reference intervals for the adult population as a whole.
Read the full publication here >
January 2018
MR-proADM in Paediatrics
Reliability of Pro-adrenomedullin and Interleukin 1β in Predicting Severity of Community-Acquired Pneumonia in Pediatric Patients
Objectives: Community-acquired pneumonia (CAP) in children is one of the most important causes of mortality and morbidity in developing countries. Therefore, it is very important for clinicians to detect the presence and severity of pneumonia.
Read the full publication here >
January 2018
MR-proADM in the Laboratory
Mid-regional proadrenomedullin (MR-proADM) reference values in serum
MR-proADM reference values in a healthy population using serum samples
2017
December 2017
MR-proADM in Emergency Department Infections
Prognostic power of biomarkers for short-term mortality in the elderly patients seen in Emergency Departments due to infections.
Objectives: To analyse and compare 30-day mortality prognostic power of several biomarkers (C-reactive protein, procalcitonin, lactate, suPAR and pro-adremomedullin) in elderly patients seen in Emergency Departments (ED) due to infections.
